Cargando…

Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi-center study

Detalles Bibliográficos
Autores principales:	Lu, A, Fang, Y, Du, X, Li, Y, Cai, Z, Yu, K, Zhao, L, Wang, B, Wu, J, Cheng, Y, Zuo, Y, Jia, Y, Tan, F, Ding, L, Lu, J, Zhang, L, Huang, X
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771971/ https://www.ncbi.nlm.nih.gov/pubmed/26918364 http://dx.doi.org/10.1038/bcj.2016.8

Ejemplares similares

Efficacy of Low Dose Clofarabine in Refractory Precursor T- Acute Lymphoblastic Leukemia
por: Choi, Jaehyuk, et al.
Publicado: (2007)

French “real life” experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia
por: Trioche, Pascale, et al.
Publicado: (2012)

Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia
por: Tse, Eric, et al.
Publicado: (2011)

Treating refractory leukemias in childhood, role of clofarabine
por: Harned, Theresa M, et al.
Publicado: (2008)

Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study
por: van Eijkelenburg, Natasha K.A., et al.
Publicado: (2018)

Clofarabine Experience in Children with Multi-Relapsed Acute Leukemia
por: Karakaş, Zeynep, et al.
Publicado: (2014)

Clofarabine in Pediatric Acute Relapsed or Refractory Leukemia: Where Do We Stand on the Bridge to Hematopoietic Stem Cell Transplantation?
por: Ramiz, Sarah, et al.
Publicado: (2023)

Patient-Level Meta-analysis of Clofarabine in Acute Lymphoblastic Leukemia
por: Jeha, Sima, et al.
Publicado: (2023)

Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
por: Gill, Harinder, et al.
Publicado: (2020)

Effectiveness and Safety of Clofarabine Monotherapy or Combination Treatment in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia: A Pragmatic, Non-interventional Study in Korea
por: Choi, Jung Yoon, et al.
Publicado: (2021)

A Real-World Study on Clofarabine and Cytarabine Combination in Patients with Relapsed/Refractory Acute Myeloid Leukemia
por: Crobu, Valeria, et al.
Publicado: (2019)

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2018)

Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2019)

Use of clofarabine for acute childhood leukemia
por: Pession, A, et al.
Publicado: (2010)

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)

Quantification of clofarabine in urine and plasma by LC-MS/MS: suitable for PK study and TDM in pediatric patients with relapsed or refractory ALL
por: Zhang, Xi, et al.
Publicado: (2022)

Successful combination chemotherapy involving clofarabine, cyclophosphamide, and etoposide for pediatric relapsed acute myeloid leukemia: A case report
por: Fujita, Sachio, et al.
Publicado: (2021)

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
por: Garrett, May, et al.
Publicado: (2019)

Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines
por: Valdez, B C, et al.
Publicado: (2014)

Targeted Treatment and Immunotherapy in High-risk and Relapsed/Refractory Pediatric Acute Lymphoblastic Leukemia
por: Graiqevci-Uka, Violeta, et al.
Publicado: (2022)

Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia
por: Weng, X-Q, et al.
Publicado: (2013)

An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia
por: Ma, Jun, et al.
Publicado: (2018)

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
por: Topp, M S, et al.
Publicado: (2018)

Clofarabine monotherapy in two patients with refractory Langerhans cell histiocytosis
por: Irie, Masahiro, et al.
Publicado: (2021)

Clofarabine treatment of KMT2Ar infantile patients with acute lymphoblastic leukemia in St. Jude Total Therapy Study 16
por: Gruber, Tanja A., et al.
Publicado: (2022)

Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype
por: Fenwarth, Laurène, et al.
Publicado: (2019)

PB2148: EFFICACY OF SMALL MOLECULE TARGET THERAPIES IN REFRACTORY OR RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA AND MOLECULAR SUBTYPING: A MULTI-CENTER REAL-WORLD EVIDENCE
por: Zhang, Y., et al.
Publicado: (2022)

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
por: Xie, Jiao, et al.
Publicado: (2023)

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
por: Laetsch, Theodore W., et al.
Publicado: (2023)

Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in paediatric patients
por: Nijstad, A. Laura, et al.
Publicado: (2021)

Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
por: Williams, Sherry, et al.
Publicado: (2018)

Clofarabine desensitization: A case report: Leukemia research reports
por: Hayes, Sarah M., et al.
Publicado: (2017)

Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen
por: Versluijs, A. Birgitta, et al.
Publicado: (2022)

P895: DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPUS
por: Fu, W., et al.
Publicado: (2022)

Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia
por: Gao, Xuan, et al.
Publicado: (2021)

PB1767: OUTCOME OF RELAPSED CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN THE SOUTH OF TUNISIA SINGLE CENTER EXPERIENCE
por: Siala, N., et al.
Publicado: (2022)

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
por: DeAngelo, Daniel J., et al.
Publicado: (2020)

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
por: Shimony, Shai, et al.
Publicado: (2022)

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
por: Gore, Lia, et al.
Publicado: (2018)

Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
por: Locatelli, Franco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bb8vsvvectpvg6dk79nj53d3i9